{"id":"placebo-as-sc-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is administered as a subcutaneous injection in phase 3 trials to serve as a comparator arm, allowing researchers to distinguish the true therapeutic effect of an investigational drug from placebo response and natural disease progression. Any observed clinical benefit in the placebo group is attributed to the placebo effect, regression to the mean, or natural history of the condition.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:35.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07498634","phase":"PHASE3","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","status":"COMPLETED","sponsor":"Zhejiang Kanova Biopharmaceutical Co., LTD","startDate":"2023-09-21","conditions":"Phase III","enrollment":323},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05075824","phase":"PHASE2","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-09","conditions":"Sickle Cell Disease","enrollment":90},{"nctId":"NCT07075640","phase":"PHASE1","title":"A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants","status":"RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2025-07-07","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT06513546","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"PLL TX AUSTRALIA PTY LTD","startDate":"2026-04-08","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":153},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT06181435","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-12-21","conditions":"Dermatitis Atopic","enrollment":589},{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT07441252","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-03-05","conditions":"Overweight or Obesity and Elevated Liver Fat","enrollment":180},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT06819891","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-12","conditions":"Moderately to Severely Active Crohns Disease","enrollment":425},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT05071664","phase":"PHASE2","title":"A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-25","conditions":"Arthritis, Psoriatic","enrollment":91},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT04882098","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-17","conditions":"Arthritis, Psoriatic","enrollment":1054},{"nctId":"NCT04929210","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-30","conditions":"Arthritis, Psoriatic","enrollment":411},{"nctId":"NCT06863961","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-01","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT07137585","phase":"PHASE1","title":"A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-09-30","conditions":"Type 2 Diabetes Mellitus, Obesity, Overweight","enrollment":30},{"nctId":"NCT04936308","phase":"PHASE3","title":"Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Arthritis, Psoriatic","enrollment":453},{"nctId":"NCT07239336","phase":"PHASE2","title":"Study of DONQ52 in Active Celiac Disease","status":"RECRUITING","sponsor":"Chugai Pharmaceutical","startDate":"2025-12-16","conditions":"Celiac Disease","enrollment":92},{"nctId":"NCT06015737","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-29","conditions":"Cutaneous Lupus Erythematosus","enrollment":302},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07459452","phase":"PHASE2","title":"Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-04","conditions":"Perennial Allergic Rhinitis","enrollment":135},{"nctId":"NCT07225686","phase":"PHASE3","title":"Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-12-19","conditions":"Obesity, Obstructive Sleep Apnea","enrollment":250},{"nctId":"NCT07137598","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-12-05","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05692180","phase":"PHASE3","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-05","conditions":"Asthma","enrollment":200},{"nctId":"NCT06819878","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-17","conditions":"Moderately to Severely Active Crohns Disease","enrollment":600},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT06588855","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-11","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":350},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT07185009","phase":"PHASE3","title":"A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-16","conditions":"Ulcerative Colitis","enrollment":671},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT07184931","phase":"PHASE3","title":"An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-01","conditions":"Crohn's Disease","enrollment":980},{"nctId":"NCT07184944","phase":"PHASE3","title":"A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-22","conditions":"Crohn's Disease","enrollment":671},{"nctId":"NCT06272487","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-02-29","conditions":"High Cardiovascular Risk, Hypertension","enrollment":375},{"nctId":"NCT07184996","phase":"PHASE3","title":"An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-08","conditions":"Ulcerative Colitis","enrollment":980},{"nctId":"NCT06557772","phase":"PHASE2","title":"A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-08-29","conditions":"Coeliac Disease, Celiac Disease","enrollment":229},{"nctId":"NCT07074977","phase":"PHASE2","title":"Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)","status":"RECRUITING","sponsor":"Galderma R&D","startDate":"2025-10-20","conditions":"Chronic Pruritus of Unknown Origin","enrollment":50},{"nctId":"NCT07375758","phase":"PHASE1, PHASE2","title":"A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Mabworks Biotech Co., Ltd.","startDate":"2026-02","conditions":"Immunoglobulin A Nephropathy","enrollment":130},{"nctId":"NCT05552157","phase":"PHASE2, PHASE3","title":"A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-22","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":280},{"nctId":"NCT05501717","phase":"PHASE1","title":"Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-08-16","conditions":"Healthy","enrollment":48},{"nctId":"NCT06280391","phase":"PHASE2","title":"A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2024-02-20","conditions":"Bronchiectasis","enrollment":312},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT06602258","phase":"PHASE2","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-09-30","conditions":"Alzheimer's Disease","enrollment":105},{"nctId":"NCT04895241","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-05-25","conditions":"Lupus Erythematosus, Systemic","enrollment":548},{"nctId":"NCT06132841","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-13","conditions":"Healthy Participants","enrollment":104},{"nctId":"NCT05592275","phase":"PHASE2","title":"A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2023-02-03","conditions":"Heart Failure, Heart Failure With Preserved Ejection Fraction","enrollment":332},{"nctId":"NCT05662241","phase":"PHASE3","title":"A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zenas BioPharma (USA), LLC","startDate":"2023-01-09","conditions":"IgG4 Related Disease","enrollment":194},{"nctId":"NCT06118099","phase":"PHASE2","title":"Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Sanofi","startDate":"2023-11-01","conditions":"Hidradenitis","enrollment":90},{"nctId":"NCT04961567","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-07-16","conditions":"Lupus Erythematosus, Systemic","enrollment":562},{"nctId":"NCT07229118","phase":"PHASE1","title":"A Study to Evaluate COR-1004 in Adult Volunteers.","status":"RECRUITING","sponsor":"Corsera Health","startDate":"2025-11-28","conditions":"Hyperlipidemia","enrollment":60},{"nctId":"NCT07306585","phase":"PHASE1","title":"The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE","status":"NOT_YET_RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-12-30","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":32},{"nctId":"NCT06103877","phase":"PHASE1","title":"A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-01","conditions":"Healthy Volunteers","enrollment":108},{"nctId":"NCT07230496","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2025-12-30","conditions":"Overweight and Obesity","enrollment":104},{"nctId":"NCT05387070","phase":"PHASE3","title":"PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism","status":"COMPLETED","sponsor":"Visen Pharmaceuticals (Shanghai) Co., Ltd.","startDate":"2021-07-28","conditions":"Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases","enrollment":81},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT05491421","phase":"PHASE1","title":"A Study of ZT002 in Healthy Participants","status":"COMPLETED","sponsor":"QL Biopharmaceutical Australia Pty Ltd","startDate":"2022-09-02","conditions":"Type 2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT03246529","phase":"PHASE3","title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioLineRx, Ltd.","startDate":"2018-03-23","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT03783377","phase":"PHASE1","title":"Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2019-03-08","conditions":"Hypertriglyceridemia, Familial Chylomicronemia","enrollment":112},{"nctId":"NCT06101095","phase":"PHASE4","title":"A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-11-29","conditions":"Eosinophilic Oesophagitis","enrollment":69},{"nctId":"NCT07059312","phase":"PHASE1","title":"A Phase 1 Study of JADE101 in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jade Biosciences, Inc.","startDate":"2025-08-17","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06407934","phase":"PHASE3","title":"A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-05-08","conditions":"Dermatitis Atopic","enrollment":1541},{"nctId":"NCT06514508","phase":"PHASE3","title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2025-12-01","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT03705234","phase":"PHASE3","title":"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2018-10-30","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":16124},{"nctId":"NCT07261644","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2025-11-07","conditions":"Ankylosing Spondylitis","enrollment":500},{"nctId":"NCT05274750","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-22","conditions":"Nasal Polyps","enrollment":276},{"nctId":"NCT06224348","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids","status":"COMPLETED","sponsor":"Sanofi","startDate":"2024-01-18","conditions":"Dermatitis Atopic","enrollment":643},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT04971785","phase":"PHASE2","title":"Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-08-09","conditions":"Nonalcoholic Steatohepatitis","enrollment":457},{"nctId":"NCT07245771","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity","status":"RECRUITING","sponsor":"Ikaria Bioscience Pty Ltd","startDate":"2025-11-04","conditions":"Obesity &Amp; Overweight","enrollment":104},{"nctId":"NCT06130566","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-08","conditions":"Dermatitis Atopic","enrollment":601},{"nctId":"NCT04743791","phase":"PHASE4","title":"Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sally E. Wenzel MD","startDate":"2022-10-17","conditions":"Asthma","enrollment":30},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT06411860","phase":"PHASE1","title":"A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Basic Science","enrollment":32},{"nctId":"NCT05162768","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)","status":"COMPLETED","sponsor":"Stealth BioTherapeutics Inc.","startDate":"2022-04-29","conditions":"Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation","enrollment":102},{"nctId":"NCT06444451","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-06-06","conditions":"Alopecia Areata","enrollment":166},{"nctId":"NCT05963022","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-08-21","conditions":"Type 2 Diabetes","enrollment":206},{"nctId":"NCT05905783","phase":"PHASE3","title":"Hidradenitis Suppurativa Study of Izokibep","status":"TERMINATED","sponsor":"ACELYRIN Inc.","startDate":"2023-06-22","conditions":"Hidradenitis Suppurativa","enrollment":258},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT03887455","phase":"PHASE3","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-03-27","conditions":"Early Alzheimer's Disease","enrollment":1906},{"nctId":"NCT04202354","phase":"PHASE1, PHASE2","title":"Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2020-03-03","conditions":"Non-alcoholic Steatohepatitis","enrollment":50},{"nctId":"NCT06944379","phase":"PHASE1","title":"ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oruka Therapeutics, Inc.","startDate":"2025-05-19","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT04856930","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2021-07-07","conditions":"Hidradenitis Suppurativa","enrollment":149},{"nctId":"NCT07178327","phase":"PHASE1","title":"Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai TTM-Bio Technology Co., Ltd","startDate":"2025-09-06","conditions":"Osteoporotic Fracture","enrollment":44},{"nctId":"NCT06243198","phase":"PHASE1","title":"A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-03-28","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo as SC Injection","genericName":"Placebo as SC Injection","companyName":"Carmot Therapeutics, Inc.","companyId":"carmot-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}